AKT1 and cancer: The results showed that combined inhibition of both the PI3K/AKT/mTOR and MAPK/ERK pathways elicited dramatic anti-tumor effects in many tumor types as compared to targeting either pathway alone40, 41, but at the cost of additional toxicity due to a small therapeutic index between normal and cancer cells.